Would a single-shot COVID-19 vaccine accelerate fight against coronavirus? gulfnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulfnews.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Follow @alexcarchidi
If you think that you missed out on the coronavirus vaccine furor in the market last year, think again. Even though
Pfizer and
Moderna have already successfully commercialized their coronavirus jabs, demand for vaccination is still far outstripping supply. For the foreseeable future, there s plenty of vaccine market share to go around.
By Reuters Staff
2 Min Read
MANILA, Dec 21 (Reuters) - The Philippines expects to receive 30 million doses of Novavax Inc’s COVID-19 vaccine by July next year, its foreign minister said on Monday, boosting the country’s effort to secure supplies to inoculate more than 100 million people.
Despite consultations with numerous vaccine makers, the Philippines has so far signed only one supply deal, with the help of its private sector, to acquire 2.6 million shots of a vaccine developed by AstraZeneca.
It plans to buy 25 million doses of a vaccine from China’s Sinovac Biotech for delivery by March and aims to secure between four and 25 million doses of vaccines from Moderna and Arcturus Therapeutics Holdings Inc.
Jan 02 2021, 2:49 PM
December 31 2020, 3:30 PM
January 02 2021, 2:49 PM
(Bloomberg Opinion) Everyone should know Cathie Wood by now.
(Bloomberg Opinion) Everyone should know Cathie Wood by now.
That s because whatever benefits central bankers bequeathed to shareholders with next-to-zero interest rates and the record $14 trillion global money supply increase in 2020, Wood beat every stock picker by betting on the innovators in DNA development who are rescuing the world from the global pandemic.
Among the 367 U.S.-based mutual funds with 60% of their $5 billion (or more) in American equities, her ARK Genomic Revolution ETF, ARK Innovation ETFÂ and ARK Next Generation Internet ETFÂ are far ahead, reaping bonanzas of 203%, 159% and 157%, respectively.